Pharmaceutical company Novo Nordisk is waiting on federal approval to sell its blockbuster GLP-1 weight-loss treatment as a ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

According to a recent Kaiser Family Foundation poll, roughly 6% of U.S. adults are currently taking GLP-1 for weight loss, ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

The rise in GLP-1 use among young women raises concerns about contraceptive efficacy and potential pregnancy risks. Learn ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Weight loss pills either reduce appetite, boost metabolism or block fat absorption. Most people lose 5% to 10% of their body ...

As broader approval for GLP-1 weight loss drugs spurs higher demand, it’s also causing employer drug spending to spike.

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

Explore CivicScience insights on GLP-1 trends—costs emerge as a barrier, but users report improved emotional wellbeing. See ...